## UNITED STATES

## SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of April 2020
001-36203
(Commission File Number)

## CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F $\square$ Form 40-F $\square$
Indicate by check mark if the registrant is submitting the Form $6-\mathrm{K}$ in paper as permitted by
Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form $6-\mathrm{K}$ in paper as permitted by
Regulation S-T Rule 101(b)(7): $\qquad$
This Report on Form 6-K is hereby incorporated by reference into the registrant's Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333195124, 333-236064, 333-209037 and 333-220644), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On April 21, 2020, Can-Fite BioPharma Ltd. (the "Company") convened a Special Meeting of Shareholders, however, the meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company's Special Meeting of Shareholders will be reconvened on Tuesday, April 28, 2020 at 4:00 p.m. (Israel time) at the Company's offices located at 10 Bareket Street, Petach Tikva, Israel.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

## Can-Fite BioPharma Ltd.

Date: April 21, 2020
By: /s/ Pnina Fishman
Pnina Fishman
Chief Executive Officer

